IP Library Granted Patent US 9,528,099
Granted Patent B2
US 9,528,099 · App. 14/743,629 · Granted Dec 27, 2016

Fusion proteins of collagen-binding domain and parathyroid hormone

Inventors: Robert C. Gensure (New York, NY); Joshua Sakon (Fayetteville, AR); Osamu Matsushita (Okayama, JP); Tulasi Ponnapakkam (New York, NY)
Assignee: National University Corporation Kagawa University
C12N9/50A61K8/64A61K8/66A61K38/29A61K38/4886A61Q7/00C07K14/635C12N9/52C12N9/6489A61K2800/86A61K2800/91C07K2319/00C07K2319/70C12Y304/24003C12Y304/24007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,528,099
App. No.
14/743,629
Granted
Dec 27, 2016
Kind
B2
Abstract

Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

Claims (16)

1. A composition comprising:

a collagen-binding polypeptide segment covalently linked to a PTH/PTHrP receptor antagonist; wherein the collagen-binding polypeptide segment is a ColH or ColG bacterial collagen binding polypeptide segment or a segment of a collagenase, wherein the PTH/PTHrP receptor antagonist comprises a peptide selected from the group consisting of residues 7-14 of SFQ ID NO: 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 8, and SEQ ID NO: 11, wherein the collagen-binding polypeptide segment comprises residues 38-158 of SEQ ID NO: 1, a fragment of at least 8 consecutive amino acids from residues 38-158 of SEQ ID NO: 1 or is at least 90% identical to residues 38-158 of SEQ ID NO: 1.

2. The composition of claim 1 , wherein the collagen-binding polypeptide segment and the PTH/PTHrP receptor antagonist are chemically crosslinked to each other or are polypeptide portions of a fusion protein.

3. The composition of claim 1 , wherein the PTH/PTHrP receptor antagonist is a polypeptide and the N-terminus of the collagen-binding polypeptide segment is linked directly or through a linker polypeptide segment to the C-terminus of the PTH/PTHrP receptor antagonist polypeptide.

4. The composition of claim 1 , wherein the composition further comprises residues 37-130 of SEQ NO: 2 covalently linked to the collagen binding polypeptide segment.

5. The composition of claim 1 , wherein the collagen binding polypeptide segment comprises residues 38-158 of SEQ ID NO 1.

6. The composition of claim 1 , wherein the composition comprises SEQ NO: 10.

7. The composition of claim 1 , wherein the PTH/PTHrP receptor antagonist consists of a polypeptide selected from the group consisting of residues 7-14 of SEQ ID NO 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7 and residues 7-34 of SEQ ID NO: 8.

8. A method of promoting hair growth in a mammal comprising: administering the composition of claim 1 to the mammal in an amount effective to promote hair growth.

9. The method of claim 7 , wherein the composition is administered locally at the site of desired hair growth.

10. The method of claim 7 , wherein the administration is by subcutaneous or intradermal injection.

11. The method of claim 7 , wherein the mammal is afflicted with chemotherapy-induced alopecia.

12. A method of treating or reducing renal osteodystrophy in a mammal comprising administering the composition of claim 1 to the mammal in an amount effective to reduce renal osteodystrophy or renal disease in the mammal.

13. The method of claim 12 , wherein the composition is administered by injection.

14. A method of treating bone metastasis of cancer in a mammal comprising administering the composition of claim 1 to the mammal in an effective to reduce the incidence of bone metastasis of cancer or slow the growth of metastatic cancer in the bone in the mammal.

15. The method of claim 14 , wherein the composition is administered by injection.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: MATSUSHITA, OSAMU
To: NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
Reel/Frame 039504/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: PONNAPAKKAM, TULASI; GENSURE, ROBERT C.
To: OCHSNER CLINIC FOUNDATION
Reel/Frame 039504/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2016
From: SAKON, JOSHUA
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 039504/0892 →
Continuity (4)
Division 13898058 · May 20, 2013
Division 12594547
Provisional Application 60922433 · Apr 9, 2007
Related Publication 20150284701A1 · Oct 8, 2015